首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 109 毫秒
1.
将牛αS1-酪蛋白5′调控序列约1.2 kb的片段,连接到含SV40启动子调控下β-半乳糖苷酶基因(LacZ)的PSV载体上,做为启动子,在其后连接0.76 kb的人α-乳白蛋白基因(α-LA),构建真核表达载体 αS1-LA-psv.采用组织块接种法,培养奶牛乳腺上皮细胞,经传代纯化后,对细胞接种存活率、群体倍增时间、生长曲线、形态学等生物学性状进行检测,用免疫荧光细胞染色法对培养的奶牛乳腺上皮细胞进行角蛋白18鉴定,结果表明,成功建立奶牛乳腺上皮细胞系,细胞传至20代以上时仍保持旺盛的增殖活力.将构建的真核表达载体 αS1-LA-psv 转染奶牛乳腺上皮细胞,培养24~120 h均检测到了β-半乳糖苷酶的表达;培养72 h检测到细胞中人α-乳白蛋白的表达,表达量约为0.64 g/L.实验结果表明,建立的奶牛乳腺上皮细胞系具有外源基因表达活性,得到的牛αS1-酪蛋白5′调控序列能作为启动子指导外源基因的表达,构建的真核表达载体能在体外培养的牛乳腺上皮细胞中同时表达人α-乳白蛋白和β-半乳糖苷酶.  相似文献   

2.
将牛αS1-酪蛋白5'调控序列约1.2kb的片段,连接到含SV40启动子调控下β-半乳糖苷酶基因(LacZ)的PSV载体上,做为启动子,在其后连接0.76kb的人α-乳白蛋白基因(α-LA),构建真核表达载体αS1-LA-psv.采用组织块接种法,培养奶牛乳腺上皮细胞,经传代纯化后,对细胞接种存活率、群体倍增时间、生长曲线、形态学等生物学性状进行检测,用免疫荧光细胞染色法对培养的奶牛乳腺上皮细胞进行角蛋白18鉴定,结果表明,成功建立奶牛乳腺上皮细胞系,细胞传至20代以上时仍保持旺盛的增殖活力.将构建的真核表达载体αS1-LA-psv转染奶牛乳腺上皮细胞,培养24~120h均检测到了β-半乳糖苷酶的表达;培养72h检测到细胞中人α-乳白蛋白的表达,表达量约为0.64g/L.实验结果表明,建立的奶牛乳腺上皮细胞系具有外源基因表达活性,得到的牛αS1-酪蛋白5'调控序列能作为启动子指导外源基因的表达,构建的真核表达载体能在体外培养的牛乳腺上皮细胞中同时表达人α-乳白蛋白和β-半乳糖苷酶.  相似文献   

3.
将牛αS1-酪蛋白5′调控序列约1.2 kb的片段,连接到含SV40启动子调控下β-半乳糖苷酶基因(LaeZ)的PSV载体上,做为肩动子,在其后连接0.76kb的人仅α-乳白蛋白基凼(α-LA),构建真核表达载体αS1-LA-psv.采用组织块接种法,培养奶牛乳腺上皮细胞,经传代纯化后,对细胞接种存活率、群体倍增时间、生长曲线、形态学等生物学性状进行检测,用免疫荧光细胞染色法对培养的奶牛乳腺上皮细胞进行角蛋白18鉴定,结果表明,成功建立奶牛乳腺上皮细胞系,细胞传至20代以上时仍保持旺盛的增殖活力.将构建的真核表达载体αS1-LA-psv转染奶牛乳腺上皮细胞,培养24~120h均检测到了β-半乳糖苷酶的表达;培养72 h检测到细胞中人α-乳白蛋白的表达,表达量约为0.64 g/L.实验结果表明,建它的奶牛乳腺上皮细胞系具有外源基因表达活性,得到的牛αS1-酪蛋白5′调控序列能作为启动子指导外源基因的表达,构建的真核表达载体能在体外培养的牛乳腺上皮细胞中同时表达人α-乳白蛋白和β-半乳糖苷酶.  相似文献   

4.
αS1酪蛋白是牛乳中含量最高的酪蛋白.本研究克隆了牛αS1酪蛋白5′调控序列约1.2kb的片段,应用基因重组技术将其插入lacZ基因上游,构建真核表达载体gαs1p-psv.胶原酶消化法对奶山羊乳腺上皮细胞进行了分离培养,并用免疫荧光法鉴定了乳腺上皮细胞.将重组载体转染奶山羊乳腺上皮细胞,在细胞培养液中,转染后24h可以检测到lacZ基因的表达,之后表达水平有逐渐升高的趋势,72h开始降低,144h降到最低;在细胞破碎液中,转染后24h表达水平最高,之后表达水平有逐渐降低的趋势,144h降到最低.转染细胞的第1代表达水平最高,随细胞传代表达水平降低,传到第3代时基本检测不到表达产物.对转染后的细胞进行了β-半乳糖苷酶原位细胞染色.实验证明,得到的牛αS1酪蛋白5′调控序列能指导外源基因在奶山羊乳腺上皮细胞中表达.  相似文献   

5.
《生物学通报》2009,(12):35-35
11月25日,由我国著名动物胚胎工程专家、西北农林科技大学教授张涌历时10年主持培育的世界首例转人防御素基因克隆奶牛在陕西诞生。科研人员通过基因工程的方法,将人特异表达的防御素基因与奶牛β-酪蛋白启动子结合。得到人防御素基因乳腺特异性高效表达载体,并将其导入高产的奶牛皮肤成纤维细胞中,  相似文献   

6.
αS1酪蛋白是牛乳中含量最高的酪蛋白.本研究克隆了牛αS1酪蛋白5′调控序列约1.2 kb的片段,应用基因重组技术将其插入 lacZ 基因上游,构建真核表达载体gαs1p psv.胶原酶消化法对奶山羊乳腺上皮细胞进行了分离培养,并用免疫荧光法鉴定了乳腺上皮细胞. 将重组载体转染奶山羊乳腺上皮细胞,在细胞培养液中,转染后24 h可以检测到 lacZ 基因的表达,之后表达水平有逐渐升高的趋势,72 h开始降低,144 h降到最低;在细胞破碎液中,转染后24 h表达水平最高,之后表达水平有逐渐降低的趋势,144 h降到最低.转染细胞的第1代表达水平最高,随细胞传代表达水平降低,传到第3代时基本检测不到表达产物. 对转染后的细胞进行了β 半乳糖苷酶原位细胞染色. 实验证明,得到的牛αS1酪蛋白5′调控序列能指导外源基因在奶山羊乳腺上皮细胞中表达.  相似文献   

7.
哺乳动物的β-防御素是一类具有广谱抗微生物活性的阳离子小肽.为了克隆和分析犬β防御素-1基因,并建立一套在HEK293T细胞中高效表达犬β防御素-1的方法,本研究采用RT-PCR方法从犬睾丸组织中扩增出犬β防御素-1(cBD-1)的cDNA基因,并将其克隆到pcDNA3.1A载体中,构建了犬β防御素-1基因的真核表达载体pcDNA3.1A-cBD-1,经磷酸钙介导转染HEK293T细胞进行表达.结果表明:克隆的犬β防御素-1基因序列与已发表序列(GenBank 编号:NM-001024641)的同源性为99.7%.表达犬β防御素-1经Western-blot检测,证明构建的犬β防御素-1基因表达载体能够在真核细胞中表达,表达产物能够分泌到细胞外.为进一步研究犬β防御素的功能奠定了基础.  相似文献   

8.
人整合素β3亚基真核表达载体的构建及表达   总被引:1,自引:0,他引:1  
构建人整合素β3亚基全读码框(ORF)基因真核表达载体,为探讨整合素β3作为汉坦病毒(Hantavirus,HV)受体的特异性奠定基础.根据已公布的序列设计引物,用PCR方法从原核质粒中扩增出人整合素分子β3亚基ORF基因,应用TA克隆将其插入pcDNA3.1/V5-His-TOPO载体中,采用酶切和PCR鉴定,选取初筛正向插入的阳性克隆进行测序,序列分析表明与公布的人整合素β3亚基ORF核苷酸序列基本一致,并通过脂质体介导转染至CHO细胞中进行瞬时表达,经间接免疫荧光法检测证实pcDNA3.1-β3能在宿主细胞中高效表达.  相似文献   

9.
目的制备乳腺生物反应器所必需的乳腺特异性表达的调控序列,并验证其指导外源基因表达的能力.方法用PCR法从奶牛染色体上分5段扩增出了全长8.2Kb的牛β-乳球蛋白基因,包括1.8Kb的5′侧翼区、1.7Kb的3′侧翼区及4.7Kb的gDNA区.扩增出的各片段克隆到T-载体上,酶切鉴定及序列分析均证实了所扩增片段的正确性.将五个片段与荧光素酶cDNA拼接成荧光素酶瞬时表达载体并在小鼠乳腺中瞬时表达.结果注射荧光素酶瞬时表达载体的小鼠乳汁中明显测出了荧光素酶活性.结论所克隆的牛β-乳球蛋白基因表达调控序列能够指导外源基因在小鼠乳腺中表达.  相似文献   

10.
催乳素(prolactin,PRL)可通过PRL-PRLR-JAK/STAT信号通路促进乳腺发育,启动并维持泌乳。为了探讨调控PRL基因表达对奶水牛产奶量的影响,该研究构建了乳腺特异性表达PRL基因的核移植载体并检测了其有效性。首先,利用RT-PCR方法克隆得到804 bp的水牛PRL基因编码区;而后逐步采用酶切加连接方法,依次将PRL基因、β-酪蛋白(β-casein,BCN)启动子和标记基因插入p IFN-BCNpoly A质粒中,构建得到14.2 Kb的转PRL基因载体。将表达载体瞬时转染人Bcap-37细胞系,经RT-PCR检测发现,目的基因PRL可在该细胞系中表达。将该载体转入水牛胎儿成纤维细胞中,通过核移植法获得了转PRL基因水牛克隆胚胎。该文结果表明,所构建的PRL核移植载体可表达PRL基因,并可用于生产转PRL基因克隆水牛胚胎。  相似文献   

11.
Gene expression profiles of 14 common tumors and their counterpart normal tissues were analyzed with machine learning methods to address the problem of selection of tumor-specific genes and analysis of their differential expressions in tumor tissues. First, a variation of the Relief algorithm, “RFE_Relief algorithm” was proposed to learn the relations between genes and tissue types. Then, a support vector machine was employed to find the gene subset with the best classification performance for distinguishing cancerous tissues and their counterparts. After tissue-specific genes were removed, cross validation experiments were employed to demonstrate the common deregulated expressions of the selected gene in tumor tissues. The results indicate the existence of a specific expression fingerprint of these genes that is shared in different tumor tissues, and the hallmarks of the expression patterns of these genes in cancerous tissues are summarized at the end of this paper.  相似文献   

12.
13.
14.
Gene expression profiles of 14 common tumors and their counterpart normal tissues were analyzed with machine learning methods to address the problem of selection of tumor-specific genes and analysis of their differential expressions in tumor tissues. First, a variation of the Relief algorithm, "RFE_Relief algorithm" was proposed to learn the relations between genes and tissue types. Then, a support vector machine was employed to find the gene subset with the best classification performance for distinguishing cancerous tissues and their counterparts. After tissue-specific genes were removed, cross validation experiments were employed to demonstrate the common deregulated expressions of the selected gene in tumor tissues. The results indicate the existence of a specific expression fingerprint of these genes that is shared in different tumor tissues, and the hallmarks of the expression patterns of these genes in cancerous tissues are summarized at the end of this paper.  相似文献   

15.
16.
17.
18.
Recombinant antibodies are increasingly used as therapeutics for a wide variety of diseases. Generation of cell lines expressing high levels of recombinant antibody typically requires labor-intensive cloning and screening steps. We describe a mammalian expression system for the high-level production of full-length antibody molecules. It has been shown that the dihydrofolate reductase (DHFR) selectable marker can be divided into two fragments that, with the aid of a leucine zipper, can re-associate to form an active molecule. Using bicistronic vectors, we linked the expression of each antibody chain to the expression of a DHFR fragment. Survival in selective media requires expression of both DHFR fragments that, by virtue of these vectors, also selects for the expression of both antibody chains. Initial pools produced 5 microg of Ab/10(6) cells/d (qP = microg/10(6) cells/d). Expression of each antibody chain in conjunction with a portion of DHFR also leads to concurrent amplification of both antibody chains in the presence of methotrexate, a DHFR inhibitor, and results in a two- to fivefold increase in antibody production with basal qPs ranging from 10-25 ug/10(6) cells/d. Shake-flask cultures of amplified pools produced up to 600 mg/L of antibody in 7 days. This system allows for rapid generation of antibodies without cloning and greatly simplifies selection of cell lines for the production of potential antibody therapeutics.  相似文献   

19.
An expression vector system for stable expression of oncogenes.   总被引:3,自引:0,他引:3       下载免费PDF全文
  相似文献   

20.
Mining gene expression profiles: expression signatures as cancer phenotypes   总被引:6,自引:0,他引:6  
Many examples highlight the power of gene expression profiles, or signatures, to inform an understanding of biological phenotypes. This is perhaps best seen in the context of cancer, where expression signatures have tremendous power to identify new subtypes and to predict clinical outcomes. Although the ability to interpret the meaning of the individual genes in these signatures remains a challenge, this does not diminish the power of the signature to characterize biological states. The use of these signatures as surrogate phenotypes has been particularly important, linking diverse experimental systems that dissect the complexity of biological systems with the in vivo setting in a way that was not previously feasible.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号